Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06348264
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-30
Brief Title:
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive High-risk Salivary Duct Carcinoma
Sponsor:
Peking University First Hospital
Organization:
Peking University First Hospital
Study Overview
Official Title:
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive High-risk Salivary Duct Carcinoma a Single-arm Phase 2 Trial
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy ADT in participants with androgen receptor AR positive high-risk salivary duct carcinoma SDC
The procedures include screening treatment and follow-up period The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist LHRHa for up to 2 years
The procedures include screening treatment and follow-up period The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist LHRHa for up to 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None